Skip to content ↓

In the Media

Media Outlet:
Financial Times
Publication Date:

Co-founded by Prof. Feng Zheng, Beam Therapeutics, which uses CRISPR to treat disease, has secured $87 million in initial funding, reports Clive Cookson for Financial Times. Beam is the first company to use base editing, which changes the chemical “letters” of genetic code without cutting it, similar to “moving from scissors-and-paste to editing text with a sharp pencil,” explains Cookson. 

Related News